Zheng Wei reports 9.0% stake in Connect Biopharma (CNTB) via amended 13G

Rhea-AI Filing Summary

Connect Biopharma Holdings Ltd — Amendment to a Schedule 13G filing reporting that Zheng Wei beneficially owns 5,015,960 Ordinary Shares, representing 9.0% of the class as of December 31, 2025.

Shares outstanding were 55,903,513 Ordinary Shares as of October 31, 2025, provided as context from the issuer's Form 10-Q.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 08:52 PM Learn about SEC filing dates

FAQ

What stake does Zheng Wei report in CNTB?

Zheng Wei reports beneficial ownership of 5,015,960 Ordinary Shares, equal to 9.0% of the class as of December 31, 2025. This figure is the filing's reported beneficial ownership amount.

How many shares outstanding does CNTB report in this filing?

The filing cites 55,903,513 Ordinary Shares outstanding as of October 31, 2025, drawn from the issuer's referenced Form 10-Q. That outstanding count is presented as contextual background.

Does this Schedule 13G/A indicate changes in voting or dispositive power?

Yes. The filing states the Reporting Person has sole voting power and sole dispositive power over 5,015,960 shares, with no shared voting or dispositive power reported in the amendment.

What type of filing is this and what does it mean for CNTB ownership disclosure?

This is an amended Schedule 13G filing, which updates a passive investor's beneficial ownership disclosure. It reports the holder's stake and voting/dispositive powers without indicating a change in transaction activity.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 4)

Connect Biopharma Holdings Ltd

(Name of Issuer)

Ordinary Shares, par value $0.000174 per share

(Title of Class of Securities)

207523101

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 207523101

1

Names of Reporting Persons

Zheng Wei

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,015,960.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,015,960.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,015,960.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.0 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Connect Biopharma Holdings Ltd
(b)	Address of issuer's principal executive offices: 3580 Carmel Mountain Road, Suite 200, San Diego, CA 92130
Item 2.
(a)	Name of person filing: This statement is filed on behalf of Zheng Wei (the "Reporting Person").
(b)	Address or principal business office or, if none, residence: The address of the Reporting Person is c/o Connect Biopharma Holdings Limited, 3580 Carmel Mountain Road, Suite 200, San Diego, CA 92130.
(c)	Citizenship: The Reporting Person is a citizen of the United States.
(d)	Title of class of securities: Ordinary Shares, par value $0.000174 per share
(e)	CUSIP No.: 207523101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The ownership information presented herein represents beneficial ownership of the Ordinary Shares as of December 31, 2025, based upon 55,903,513 Ordinary Shares outstanding as of October 31, 2025, as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025. The Reporting Person is the record holder of 5,015,960 Ordinary Shares.
(b)	Percent of class: 9.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 5,015,960
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 5,015,960
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Zheng Wei

Signature:	/s/ Zheng Wei
Name/Title:	Zheng Wei
Date:	02/17/2026